Goldman Sachs
MPLT

Goldman Sachs’s MapLight Therapeutics MPLT Stock Holding History

Goldman Sachs’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40.6M Buy
1,994,873
+57,705
+3% +$1.03M ﹤0.01% 1745
2025
Q4 		$34M Buy
+1,937,168
New +$32.5M ﹤0.01% 1834

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Goldman Sachs's MPLT Position: Q1 2026 in Review

Goldman Sachs increased its MapLight Therapeutics (MPLT) stake by 3% in Q1 2026, buying an estimated $1.03M and bringing the position to 1,994,873 shares worth $40.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1745.

Goldman Sachs first reported a position in MPLT in Q4 2025 and has held it in 2 quarters since. 81 funds tracked by Wall St. Rank hold MPLT as of Q1 2026.

  • Goldman Sachs held 1,994,873 shares of MapLight Therapeutics worth $40.6M as of Q1 2026.
  • Goldman Sachs bought 57,705 MapLight Therapeutics shares in Q1 2026, an estimated $1.03M.
  • MapLight Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #1745 holding.
  • Goldman Sachs first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 81 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.